Advertisement
UK markets open in 50 minutes

  • NIKKEI 225

    37,649.53
    -810.55 (-2.11%)
     

  • HANG SENG

    17,212.37
    +11.10 (+0.06%)
     

  • CRUDE OIL

    82.94
    +0.13 (+0.16%)
     

  • GOLD FUTURES

    2,330.90
    -7.50 (-0.32%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,494.25
    -1,924.82 (-3.60%)
     

  • CMC Crypto 200

    1,390.27
    +7.70 (+0.56%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th

Marketwired

BOSTON, MA--(Marketwired - January 29, 2018) - Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a Key Opinion Leader (KOL) Event in New York on Tuesday, February 6th from 8-10:30 AM EDT.

The KOL event will feature world-class thought leaders in immuno-oncology and respiratory diseases, followed by a company presentation. The event will include presentations from:

  • Michael A. Curran, PhD, Assistant Professor in the Department of Immunology and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform at MD Anderson Cancer Center.

  • David H. Ilson, MD PhD, Medical Oncologist and Attending Physician at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Medical College.

  • Gary Anderson, PhD, FThorSoc, FERS, Professor in the Medical Faculty at the University of Melbourne and Director of the Centre for Lung Health Research.

  • Bruce Levy, MD, Parker B. Francis Professor of Medicine at Brigham and Women's Hospital and the Chief of the Pulmonary and Critical Care Division.

The event will be accessible via a live webcast through this link beginning at 8am on February 6th.

ADVERTISEMENT

In-person attendance is by invitation only. For more information please contact Clayton Robertson at crobertson@troutgroup.com.

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.